

# The Future of APC Management in Polymetastatic Disease

**William K. Oh, MD**

**Deputy Director, Tisch Cancer Institute  
Chief, Hematology and Medical Oncology  
Icahn School of Medicine at Mount Sinai**



**@williamohmd**




**Mount  
Sinai**

# Disclosures

Consultant/SAB: Amgen, Astellas, Bayer, Astra-Zeneca, Genzyme-Sanofi, Janssen, CPS Diagnostics, Bellicum Pharmaceuticals, Sema4



# The Past



# Ten-Year Survival in Patients with Metastatic Prostate Cancer



- 794 evaluable patients in S8894
- **7% lived >10 years**
- Independent predictors of survival:
  - Lower PSA, min disease, no pain, lower Gleason
- Only 13% of long term survivors could be predicted (in contrast to 98% of those who died within 5 years)

# Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases

Rami Klaff, Anders Berglund\*, Eberhard Varenhorst, Per Olov Hedlund<sup>†</sup>, Morten Jónler<sup>‡</sup>, Gabriel Sandblom<sup>§</sup> and the Scandinavian Prostate Cancer Group (SPCG) Study No. 5

- N=915
- **4.4% pts survived >10 yrs**
- Independent predictors of survival:
  - PS 0-1
  - Limited bone mets
  - PSA < 231 ng/ml

# The Present



# The Present

- Serial systemic therapy is ***standard***
  - ADT, ART, chemo, bone-targeted Rx
- Local or metastasis-directed therapy is ***investigational***
  - Surgery, radiotherapy
- Earlier intervention in some circumstances improve outcome (mHSPC>mCRPC)




# Change in outcomes for mCRPC since 2010

	N (%)	Median OS (95% CI)	5-yr OS (SE)	HR (95% CI)	P-value
Cohort A 2004-2007	317 (54%)	2.2 yrs (2 – 2.4)	10% (1.7)	1	<0.0001
Cohort B 2010-2013	266 (46%)	2.8 yrs (2.5 – 3.2)	26% (3.1)	0.69 (0.57 – 0.83)	

# The Future?






ImmunotherapyJoin the CausePatientsScientistsAbout CRI

LOGIN

DONATE

Join the CauseCancer Immunotherapy Month30 Facts About Immunotherapy


## IMMUNOTHERAPY FACT OF THE DAY #20: IMMUNOTHERAPY CURED JIMMY CARTER'S CANCER



### FACT OF THE DAY

“  
[After immunotherapy]  
... they didn't find any  
cancer at all.”

– JIMMY CARTER  
Former U.S. President



“[After immunotherapy] ... they didn't find any cancer at all.”

### RELATED LINKS

- Immunotherapy Fact of the Day #1
- Immunotherapy Fact of the Day #2
- Immunotherapy Fact of the Day #3
- Immunotherapy Fact of the Day #4
- Immunotherapy Fact of the Day #5
- Immunotherapy Fact of the Day #6
- Immunotherapy Fact of the Day #7
- Immunotherapy Fact of the Day #8
- Immunotherapy Fact



Subscribe

SCIENTIFIC  
AMERICAN®

Cart 0


Sign In | Stay Informed

MEDICINE

# Can We Truly “Cure” Cancer?


Pres. Obama laid out a moon-shot target of knocking out cancer, but cancer is not one disease—it’s many


By Dina Fine Maron on January 14, 2016 [أعرض هذا باللغة العربية](#)



On January 12 Pres. Barack Obama laid out an aspirational plan in his final State of the Union to “cure cancer.” Credit: ©iStock

# Pubmed Citations: “Cancer” + “Cure”






## Childhood Leukemia Survival

Pui. NEJM 2005


## A Radical Prostatectomy, Any Age



## Prostate Cancer Survival

Bill-Axelsson. NEJM 2018


# Cancers May Remain Dormant For Many Years



# A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer




Matthew J. O'Shaughnessy, Sean M. McBride, Hebert Alberto Vargas, Karim A. Touijer, Michael J. Morris, Daniel C. Danila, Vincent P. Laudone, Bernard H. Bochner, Joel Sheinfeld, Erica S. Dayan, Lawrence P. Bellomo, Daniel D. Sjoberg, Glenn Heller, Michael J. Zelefsky, James A. Eastham, Peter T. Scardino, and Howard I. Scher



- 4/20 (20%) achieved PSA<0.02 with recovered T
- “Cure Paradigm”?


# Patient #1: 65 yo Urologist with mHSPC



# Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for mCRPC

- *Current approach*: monotherapy until resistance develops, then switch
- Combinations have excess toxicity
- By designing a rapidly-cycling, non-cross reactive treatment regimen, can we...?
  - treat intrinsic heterogeneity
  - prevent drug resistance
  - increase long-term disease control
  - minimize toxicity

# PRINT for mCRPC: Mount Sinai



PI: Bobby Liaw, MD

# My Predictions of the Future of Metastatic Prostate Cancer

- **Molecular characterization** of tumors will be increasingly relevant as newer targeted drugs are developed
- **Immunotherapy** in metastatic prostate cancer will be more effective
- **More combination therapies** (local and systemic) will be used
- **Functional “cures”** of metastatic prostate cancer will become more common



# Is Cure Possible in Metastatic Prostate Cancer?

Yes, if our definition is flexible



**“The question is not how to get cured, but how to live”  
–Joseph Conrad**

